This collaboration is a strong strategic and financial fit for Vector,” said William Jackson, CEO of Vector Science & Therapeutics Corp. and CEO of LyoGenesis Plus
July 28, 2026
A Digital Publication for the Practicing Medical Specialist, Industry Executive, & Investor
This collaboration is a strong strategic and financial fit for Vector,” said William Jackson, CEO of Vector Science & Therapeutics Corp. and CEO of LyoGenesis Plus